In 1986, the world’s first monoclonal therapeutic drug, Orthoclone (OKT3), was approved by the FDA for its use in preventing rejection reactions during organ transplantation. Since then, antibody drugs have started gaining traction and incited an increasing number of research in this area. By the end of January 2023, the FDA has approved 119 antibody […]
Human carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), initially discovered in colon cancer by Gold and Freeman in 1965 [1] [2], has long served as a pivotal tumor marker for clinical detection and diagnosis of colorectal cancer. Recent advancements in CEACAM5 research have unveiled its potential as a target for developing novel cancer therapeutics. Notably, […]
In June 2023, BioNTech presented the first human trial data of BNT211 at the American Society of Clinical Oncology (ASCO). BNT211 is a CLDN-6-targeting CAR-T cell therapy in combination with a CLDN6-encoding mRNA vaccine (CARVac). mRNA vaccines stimulate the expansion of CAR-T cells in the patients’ body by inducing the expression of CLDN6 on the surface of antigen-presenting cells, […]